Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKinsey
Merck
Medtronic
Mallinckrodt

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LGX818

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug LGX818?

LGX818 is an investigational drug.

There have been 19 clinical trials for LGX818. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Rectal Neoplasms. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.

There are twenty-one US patents protecting this investigational drug and three hundred and twenty-one international patents.

Recent Clinical Trials for LGX818
TitleSponsorPhase
Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal CancerArray BioPharmaPhase 1/Phase 2
Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal CancerBristol-Myers Squibb (BMS)Phase 1/Phase 2
Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal CancerUniversity of California, San FranciscoPhase 1/Phase 2

See all LGX818 clinical trials

Clinical Trial Summary for LGX818

Top disease conditions for LGX818
Top clinical trial sponsors for LGX818

See all LGX818 clinical trials

US Patents for LGX818

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LGX818   Start Trial Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate Array BioPharma Inc. (Boulder, CO)   Start Trial
LGX818   Start Trial Compounds and compositions as protein kinase inhibitors IRM LLC (Hamilton, BM) Novartis AG (Basel, CH)   Start Trial
LGX818   Start Trial 3,4-diarylpyrazoles as protein kinase inhibitors Nerviano Medical Sciences S.R.L. (Nerviano, IT)   Start Trial
LGX818   Start Trial 3,4-diarylpyrazoles as protein kinase inhibitors Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LGX818

Drugname Country Document Number Estimated Expiration Related US Patent
LGX818 Argentina 077975 2029-08-28   Start Trial
LGX818 Australia 2010286569 2029-08-28   Start Trial
LGX818 Canada 2771775 2029-08-28   Start Trial
LGX818 China 102725283 2029-08-28   Start Trial
LGX818 China 103896921 2029-08-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
McKinsey
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.